Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM), Medtronic (MDT) and Insmed (INSM) with bullish sentiments.

Introducing TipRanks MCP for Agents

• Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
• Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Cullinan Management (CGEM)

In a report released yesterday, Julian Harrison from BTIG reiterated a Buy rating on Cullinan Management, with a price target of $38.00. The company’s shares closed last Wednesday at $12.05.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 41.3% and a 51.5% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Mereo Biopharma Group Plc. ;'>

Currently, the analyst consensus on Cullinan Management is a Strong Buy with an average price target of $33.56, implying a 155.4% upside from current levels. In a report issued on June 7, Morgan Stanley also maintained a Buy rating on the stock with a $30.00 price target.

See today’s best-performing stocks on TipRanks >>

Medtronic (MDT)

Bank of America Securities analyst Travis Steed maintained a Buy rating on Medtronic today and set a price target of $110.00. The company’s shares closed last Wednesday at $80.25.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 0.9% and a 48.7% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Inspire Medical Systems. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $98.52 average price target, implying a 19.8% upside from current levels. In a report issued on June 4, BTIG also upgraded the stock to Buy with a $90.00 price target.

Insmed (INSM)

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Insmed, with a price target of $214.00. The company’s shares closed last Wednesday at $91.88.

According to TipRanks.com, Zemansky is a 5-star analyst with an average return of 14.8% and a 49.4% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inhibikase Therapeutics, and Acumen Pharmaceuticals. ;'>

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $201.00, which is a 104.5% upside from current levels. In a report issued on May 28, Barclays also maintained a Buy rating on the stock with a $237.00 price target.

Read More on CGEM:

Disclaimer & DisclosureReport an Issue

• Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
• Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
• Cullinan Therapeutics reports CLN-978, velinotamig data
• Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential
• Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data